Cargando…
Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
BACKGROUND: Recent meta-analyses have shown that sodium-glucose cotransporter 2 (SGLT-2) inhibitors alleviate chronic kidney disease and acute kidney injury in diabetic patients. In this study, we aimed to investigate the effect of empagliflozin on renal ischemia/reperfusion (I/R) in nondiabetic rat...
Autores principales: | Ala, Moein, Khoshdel, Mohammad Reza Fallahpour, Dehpour, Ahmad Reza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816566/ https://www.ncbi.nlm.nih.gov/pubmed/35126806 http://dx.doi.org/10.1155/2022/1197061 |
Ejemplares similares
-
Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats
por: Seefeldt, Jacob Marthinsen, et al.
Publicado: (2021) -
Nobiletin ameliorates hepatic ischemia and reperfusion injury through the activation of SIRT-1/FOXO3a-mediated autophagy and mitochondrial biogenesis
por: Dusabimana, Theodomir, et al.
Publicado: (2019) -
Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats
por: Kim, Sua, et al.
Publicado: (2019) -
Empagliflozin protects against renal ischemia/reperfusion injury in mice
por: Wang, Qifeng, et al.
Publicado: (2022) -
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
por: Zou, Rongjun, et al.
Publicado: (2022)